Suppliers / Laboratorios Liomont, S.A. de C.V

Laboratorios Liomont, S.A. de C.V

Mexico Updated 9 July 2026

Laboratorios Liomont, S.A. de C.V is a finished-dose manufacturer based in Mexico. It appears in 98 regulatory filings across 4 regulators, without an active US DMF or CEP on file. Its filings concentrate with DIGEMAPS (DO), ARCSA (EC) and MINSA (CR). Its GMP standing is certified by COFEPRIS (MX), US FDA and EMA, among 4 authorities. Its most recent recorded inspection, by US FDA, closed on 4 August 2023 as VAI. Customs aggregates show $2.2M of exports covering 166 molecules to 15 destinations in 2023.

0
active US DMFs
0
valid CEPs
5
registered plants 1 with an FDA FEI number
98
filings across 4 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
3 of 3 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 4 August 2023 VAI US FDA
  • 15 December 2017 NAI US FDA
  • 19 October 2012 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Mexico D.F., Colombia Not on file
Ciudad De Mexico, Mexico Not on file
Ocoyoacac, Mexico Not on file
Mexico, Mexico 3003948827
Cuajimalpa de Morelos, Mexico Not on file

Filings and GMP by regulator

Regulator Filings GMP certificates
DIGEMAPS (DO) 37 None
ARCSA (EC) 35 None
MINSA (CR) 22 None
COFEPRIS (MX) 4 4
US FDA None 1
EMA None 1
INVIMA (CO) None 1

Scale

Year Revenue Exports Destinations
2023 Not reported $2.2M 15
2022 Not reported $2.7M 13

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Laboratorios Liomont, S.A. de C.V comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 4 August 2023.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts